XTSE
MSCL
Market cap104mUSD
, Last price
CAD
Name
Satellos Bioscience Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
-14.99%
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
Net income
-25m
L+88,419.16%
CFO
-24m
L-5.52%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
As a regenerative medicine enterprise, Satellos Bioscience Inc. specializes in devising therapies for degenerative muscle disorders. Their flagship initiative centers on pioneering an oral drug therapy specifically engineered to normalize muscle stem cell polarity. This groundbreaking approach aims to reactivate the body's intrinsic mechanisms for muscle healing and regrowth. Established in 2012, the company maintains its headquarters in Toronto, Canada.
Key people
Frank Gleeson
President, Chief Executive Officer, Director · since 2021
Elizabeth Williams
Chief Financial Officer · since 2023
Courtney Wells
Senior Vice President - Clinical Development Operations · since 2023
Philip Lambert
Chief Scientific Officer · since 2023
Wildon Farwell
Chief Medical Officer · since 2025
Michael Rudnicki
Chief Discovery Officer · since 2023
Warren Whitehead
Head of Corporate Strategy · since 2023
Stephanie Brown
Director · since 2024
Selwyn Ho
Director · since 2025
William Jarosz
Director · since 2023
Iris Loew-Friedrich
Director · since 2025
Franklin Berger
Independent Director · since 2023
Independent Director · since 2018
Geoff Mackay
Independent Chairman of the Board · since 2023
Independent Director · since 2021
Adam Mostafa
Independent Director · since 2021
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||